Written by the AllMyPeptides Research Team
Retatrutide vs Tesamorelin: At a Glance
Retatrutide is an investigational incretin triple agonist (GLP-1/GIP/glucagon). Tesamorelin is a GHRH analogue that works through the growth-hormone axis. They are studied in overlapping metabolic contexts but via entirely separate mechanisms.
Research use only. Both compounds are supplied for in-vitro laboratory research. Neither is a medicine, and neither is for human or veterinary consumption, administration, or therapeutic use.
How They Work — The Key Difference
Retatrutide simultaneously activates three incretin/metabolic receptors, a mechanism studied for appetite, insulin sensitivity and energy expenditure. Tesamorelin instead stimulates the pituitary to release the body's own growth hormone (raising IGF-1), a mechanism studied for its effect on visceral fat. Incretin signalling versus growth-hormone signalling — two distinct axes.
Evidence & Regulatory Status
Their regulatory positions differ sharply. Retatrutide is investigational and not approved anywhere, currently in Phase 3 trials. Tesamorelin is FDA-approved in the US for one narrow indication (HIV-associated lipodystrophy) but has no UK marketing authorisation. Research-grade material of either is supplied for laboratory use only.
Sourcing for Research
For background on incretin agonists and the growth-hormone axis, see our individual guides linked above. Verify any research peptide against a batch-matched COA. View Retatrutide and Tesamorelin product details.
Frequently Asked Questions
What is the difference between Retatrutide and Tesamorelin?+
Is Retatrutide or Tesamorelin approved?+
Are they used for the same thing in research?+
Related Guides
Products discussed in this guide are for research and laboratory use only. AllMyPeptides does not condone or support misuse of any research materials. Not for human or animal consumption.